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Abstract
There has been no extensive characterization of the effects of Ginsenoside Rg1, a pharmacological
active component purified from the nature product ginseng, in an Alzheimer's disease mouse
model. The well-characterized transgenic Alzheimer disease (AD) mice over expressing amyloid
precursor protein (APP)/Aβ (Tg mAPP) and nontransgenic (nonTg) littermates at age of 6 and 9
month were treated with Rg 1 for three months via intraperitoneal injection. Mice were then
evaluated for changes in amyloid pathology, neuropathology and behavior. Tg mAPP treated with
Rg1 showed a significant reduction of cerebral Aβ levels, reversal of certain neuropathological
changes, and preservation of spatial learning and memory, as compared to vehicle-treated mice.
Rg1 treatment inhibited activity of γ-secretases in both Tg mAPP mice and B103-APP cells,
indicating the involvement of Rg1 in APP regulation pathway. Furthermore, administration of Rg1
enhanced PKA/CREB pathway activation in mAPP mice and in cultured cortical neurons exposed
to Aβ or glutamate –mediated synaptic stress. Most importantly, the beneficial effects on
attenuation of cerebral Aβ accumulation, improvement in neuropathological and behavioral
changes can be extended to the aged mAPP mice, even to 12-13 months old mice that had
extensive amyloid pathology and severe neuropathological and cognitive malfunction. These
studies indicate that Rg1 has profound multi-faced and neuroprotective effects in an AD mouse
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model. Rg1 induces neuroprotection through ameliorating amyloid pathology, modulating APP
process, improving cognition, and activating PKA/CREB signaling. These findings provide a new
perspective for the treatment of AD and demonstrate potential for a new class of drugs for AD
treatment.
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1. Introduction
Alzheimer's disease (AD) is defined by the progressive impairment in memory and
cognition and by the presence of two major pathological hallmarks, accumulation of β-
amyloid protein (Aβ) and formation of neurofibrillary tangles composed of
hyperphosphorylated tau. Aβ, a key constituent of amyloid plaque, is a neurotoxic peptide
that contributes to neuronal, synaptic and cognitive malfunction in an Aβ rich environment
found in human AD and the AD mouse model. Thus, strategies that reduce Aβ levels in the
brain and improve cognitive function are critical for prevention and/or halting of AD
progression.
Ginseng, a drug used in traditional Chinese medicine that has a wide range of
pharmacological effects, has been empirically used to alleviate many ailments, particularly
those associated with aging and memory deterioration [1-3]. Rg1, one of the bioactive
compounds in ginseng crosses the blood-brain barrier [4]. Several studies provide evidence
of its neurotrophic, neuroprotective and anti-aging properties [5-8]. Pretreatment with Rg1
improved viability in cells injured by Aβ, reduced the levels of intracellular Aβ 1-42, and
attenuated the activation of caspase-3 and apoptosis [9-11]. Furthermore, recent studies
demonstrated that administration of ginsenosides including Rg 1 reduced cerebral Aβ in Tg
2576 mice [12], an AD mouse model as well as aging mice [13]. However, the mechanisms
underlying Rg1-involved attenuation of Aβ accumulation and improvement in learning and
memory in an Aβ-rich environment remain unclear.
Aβ1-40 and Aβ1-42 amino acid peptides generated by endoproteolysis of the Type I
membrane protein, amyloid precursor protein(APP) [14]. Aβ formation involves the
sequential cleavage of amyloid precursor protein (APP) by two proteases, the β- and γ-
secretases [15]. β secretase cleaves APP at the N-terminus to form APP-CTF-β (C99), which
is subsequently cleaved by a multi-protein γ-secretase complex that results in generation of
the Aβ peptide and a smaller APP-CTF-γ. It follows then that γ secretase is a potential prime
drug target for the treatment of Alzheimer's disease. However, it is unclear whether Rg1 is
involved in regulation of the APP process via γ secretase.
Tg mAPP mice have been well characterized with respect to mitochondrial function and
neuropathological, behavioral and electrophysiological endpoints [16-23]. The strengths of
this model include the rapid accumulation of Aß (started at 2-4 months; plaque formation at
6 months), decreased density of presynaptic terminals, abnormalities in synaptic,
electrophysiological and behavioral changes. Importantly, there is no report on studying Rg1
in this model with overexpression of human Aβ including APP process and
neuropathological changes. Thus, it would be essential and logical for choosing an
aggressive AD model to determine the impact of Rg1 on neuronal and cognitive function.
The goals of the present study are: 1) to fully assess the effects of Rg 1 on cerebral Aβ
accumulation, amyloid pathology, neuronal function, and learning/memory capacity in a
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well-characterized mouse model for AD; and 2) to elucidate the pathways affected by Rg1
that suppress Aβ production and improve neuronal and cognitive function. Results generated
from the study would provide substantial evidence for preclinical translation study of Rg1 as
a new therapeutic agent for prevention of AD and slowing of the disease process.
2. Material and Methods
2.1 Tg mice and cell culture
All animal experiments were approved by the Institutional Animal Care and Use Committee
of Columbia University and conformed to the guidelines outlined in the National Institutes
of Health Guide for Care and Use of Laboratory Animals (NIH Pub. No. 85-23, 1996).
Transgenic (Tg) mice with neuronal overexpression of a mutant human form of amyloid
precursor protein (Tg mAPP, J-20 line, originally provided by Dr. Lennart Mucke,
University of California, San Francisco) driven by the platelet-derived growth factor
(PDGF) B-chain promoter were used in this study. These Tg mice are a well-established
mouse model for the Alzheimer disease and exhibit many features of AD neuropathology
[16, 18, 24], and have been used in previously published studies [17-21, 25]. Tg mice were
divided into four groups: mAPP and nonTg littermate control mice treated with vehicle
(PBS) or Rg1 in PBS), 5-7 mice per group. Rg1 (10 mg/kg based on the previous study [13])
was intraperitoneally injected daily, starting at age of 6 or 9-10 months for a period of three
months.
For cellular studies, cortical neurons were prepared from mouse embryos at day 16 of
gestation. Rat neuroblastoma B103 cells stably expressing human wild-type (wt) APP
(B103-wtAPP) were kindly provided by Tony Wyss-Coray [26].
2.2. Reagents
Ginseng Rg1 (molecular weight 800, purity 98%) was provided by the Department of
Biochemistry of Jilin University, China.
2.3. Immunohistochemistry
The acetycholinesterase (AChE) activity was determined by the change in AChE density
(area occupied) in brain region (entorhinal cortex). After 6 min of perfusion with saline,
mice brains were divided sagittally in half; one half was immersed in paraformaldehyde
(4%) for 26 hr. Serial vibratome sections (20 μm, two sections from each mouse) were
incubated with the mixture of the two mediums: (A) 5 mg of acetylthiocholine iodide, 6.5
mL of 0.1-mmol/L acetate buffer (pH 6.0), 0.5 ml of 30-mmol/L copper sulphate, 1.0 ml of
distilled water, and 0.2 mL of 4-mmol/L iso octamethyl pyrophosphoramide (iso OMPA);
and (B) 1.0 ml of 5-mmol/L potassium ferricyanide at 37°C for 5 minutes and rinse with tap
water for 10 second. Following this, they were developed with freshly prepared 3-3′ diamino
benzidine tetrahydrochloride (25 mg in 100 mL of 0.05-mol/L phosphate buffer [pH 7.0]),
containing 0.015% H202 for 5 minutes at room temperature. Afterward, wash with tap
water, dehydrate and mount. Acetylcholine esterase (AChE) activity was analyzed
histochemically by the area occupied by AChE-positive staining neuritis in the entorhinal
cortex (the area in which cholinergic neuritis is prominent) in the brain using MetaMorph
software as previously described [18, 27]. Sections were also reacted with anti-Aß antibody
3D6 (dilution 1:1000) to identify Aß deposits. Areas with Aß plaques were analyzed using
MetaMorph software evaluating multiple sections of the same level in each animal group.
To ensure objective assessments and reliability of the results, brain sections from mice in
any given experiment were blind coded and processed in parallel. Codes were revealed only
after the analysis was completed.
Fang et al. Page 3














The brain tissue was extracted with 8 volumes of guanidine-Tris buffer (5.0M Guanidine
HCl /50mM Tris-HCl, pH 8.0). The homogenates were mixed for 3-4 hours at room
temperature. The specific human Aβ1-40 and human Aβ1-42 levels in brain tissue and
cultured medium of B103-wtAPP cells derived from Rg1 (5μM or 10 μM) or vehicle
treatment for 48h were measured by ELISA kit following the manufacture's instructions
(Invitrogen, CA).
2.5. γ-Secretase activity
γ-secretase activity was measured as previously described [28]. Freshly dissected mouse
cerebral cortex was homogenized in homogenization buffer (10mM MOPS, pH 7.0, 10mM
KCL, 1× complete protease inhibitor cocktail) and centrifuged at 2500 rpm for 15 minutes at
4 °C. The supernatant was collected and centrifuged at 14000 rpm for 20 minutes at 4 °C.
The pellet was rinsed once in homogenization buffer and then resuspended in assay buffer
(150mM sodium citrate, pH 6.4, 1× complete protease inhibitor cocktail, protein
concentration 4ug/ul). Samples were incubated at 37 °C for 2 hours, and then subjected to
Western blot. The APP-CTF antibody was used for APP-CTF-γ (6kDa) identification
(Calbiochem, USA). B103-wtAPP cells treated with Rg1 or vehicle were processed similar
to tissue samples.
2.6. PKA activity and Phosphor-CREB (p-CREB) and total-CREB (T-CREB)
Cultured cortical neurons were treated with Rg1 and/or oligomeric Aβ1-42, and then
harvested in lysis buffer (20mM MOPS, 50mM β-glycerolphosphate, 50mM sodium
fluoride, 1mM sodium vanadate, 5mM EGTA, 2mM EDTA, 1% NP40, 1mM dithiothreitol
(DTT), 1mM benzamidine, 1mM phenylmethane- sulphonylfluoride (PMSF) and 10μg/mL
leupeptin and aprotinin). PKA activity was measured using a PKA Kinase Activity Assay
Kit (Stressgen, Ann Arbor, Michigan, USA), according to the manufacturer's instructions.
Levels of p-CREB and T-CREB in cultured cortical neurons were analyzed using previous
described methods [29]. Briefly, cortical neurons were treated with Rg1 and/or oligomer
Aβ1-42, and then exposed to 50 μM glutamate (from Sigma) in a salt medium (containing
119 mM NaCl, 5 mM KCl, 2 mM CaCl2 20 mM Hepes, 1 μM glycine, 300 mM glucose) for
15min (ginsenoside Rg1 and/or Aβ1-42 were added to the culture medium to maintain stable
concentration throughout the experiments). Lysates were subjected to immunoblotting with
specific antibodies to p-CREB or T-CREB (1:1,000 dilution, Cell Signaling technology,
Danvers, MA, USA). Levels of p-CREB/T-CREB in the brains were measured using p-
CREB and T-CREB ELISA kits (Invitrogen).
2.7. Behavioral studies
Spatial learning and memory was evaluated using the radial arm water maze as previously
described [18, 19, 21, 25]. Briefly, the mouse started the task from a different randomly
chosen arm for each trial. The mouse could not use its long-term memory of the location of
the platform on previous days, but had to rely on the short-term memory of its location on
the day in question based on spatial clues that were present in the room. Each trial lasted one
minute and errors were counted each time the mouse entered the wrong arm or needed more
than 20 sec to reach the platform. After each error, the mouse was gently pulled back to the
start arm for that trial. At the end of the trial, the mouse remained on the platform for 30sec.
After four consecutive trials, the mouse was placed in its home cage for 30 min, then
returned to the maze and administered a retention trial. Testing was considered complete
when wild-type mice reached an asymptotic performance (below 2 errors on trials 4 and 5).
The generally took about 10-14 training days. The scores for each mouse on the last three
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days of testing were averaged and used for statistical analysis. The investigators were
blinded to mouse genotypes and experimental conditions.
2.7. Statistical analysis
One-way ANOVA was used for repeated measure analysis followed by Fisher's Protected
Least Significant Difference for post-hoc comparisons. STATVIEW computer software was
utilized. Results were expressed as mean ± Standard Error of the Mean (SEM).
3. Results
3.1. Effect of Rg1 on Aβ accumulation
Tg mAPP mice and nonTg littermates at age of 6 months (beginning Aβ accumulation in the
brain) and 9-10 months (severe amyloid pathology, late stage) were treated with Rg1 for 3
months to determine the effect of Rg1 on early and late stage AD pathology and to examine
whether Rg1 is able to reverse existing AD pathology. After 3 month of Rg1 treatment,
levels of Aβ1-40 and Aβ1-42 including soluble and insoluble Aβ were significantly lower in
hippocampus of Rg1-treated mAPP mice than in vehicle-treated mice (Fig 1A). Intriguingly,
similar results were obtained from mAPP mice treated with Rg1 from 9-10 to 12-13 months
of age (Fig. 1B). Consistent with this result, Aβ plaque loads were significantly reduced in
cerebral cortex including hippocampus of Rg1-treated mAPP mice, whereas vehicle-treated
mAPP mice displayed expected plentiful Aβ deposits in the brains. Quantification of Aβ
plaque load revealed that the area covered by Aβ deposits in the brains of Rg1-treated mAPP
mice was significantly reduced compared to those of vehicle-treated mAPP mice (Fig 1C-D;
P<0.01).
3.2. Effect of Rg1 on γ secretase activity
To probe the mechanism by which Rg1 reduces Aβ accumulation, we first measured γ-
secretase activity in brain tissue using an established enzymatic assay based on carboxyl
terminal fragment detection APP-CTF-γ (6 kDa) formation from membrane bound APP
[28], which is an index of γ secretase activity. Measurement of APP in the cortex of the mice
showed no differences in full length APP in mAPP mice with and without Rg1 treatment.
However, the intensity of immunoreactive bands corresponding to 6kDa APP-CTF-γ was
significantly reduced in Rg1-treated mAPP brains as compared with those from vehicle-
treated mAPP brains, indicating that γ secretase activity was significantly diminished (Fig
2A-B; P<0.05). No significant differences were found in full length APP among Rg1-treated
and vehicle-treated nonTg mice or mAPP mice (Fig. 2). Immunoblotting for β-actin verified
an equal amount protein loading in each groups of mice (Fig. 2B).
Second, to investigate the direct effect of Rg1 on γ secretases, rat neuroblastoma cells
(B103) stably transfected with wild-type APP (wtAPP) were incubated with Rg1 (5μM
and10μM) for 48 hrs, followed by analysis of APP-CTF-γ levels in the cell lysate by
immunoblotting and measurement of Aβ levels in cell-free culture medium. Aβ levels were
significantly decreased in cultured medium of Rg1-treated cells compared to those in the
vehicle-treated group (Fig. 3A; *P < 0.01; and #P < 0.05 compared to the vehicle).
Importantly, the intensities of APP-CTF-γ immunoreactive bands in the cell lysate were
significantly decreased in Rg1-treated B103-wtAPP cells compared to those without Rg1
treatment (Fig. 3B and D, APP-CTF-γ: P<0.01). Remarkably, Rg1 treatment almost
abolished γ-secretase activity as shown by prominently diminished 6kDa APP-CTF-γ
immunoreactive bands by 3-4 folds. There are no significant differences in levels of APP-
CTF-γ in cells exposed to 10 μM Rg1 compared to cells exposed to 5 μM (P=0.33) though
Rg1 5uM appears lower than 10uM in panel D. Similarly, levels of Abeta 40 in cells treated
with 10 μM Rg1 were comparable to the cells treated with 5 μM Rg1 (P=0.298). Fig. 3B
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shows the representative immunoreactive bands of the various groups. Since B103-wtAPP
cells used in our experiments are over-expressed wild-type APP gene, whereas nonTg mice
express endogenous wtAPP, the gamma secretase activity was higher in B103-wtAPP cells
than that in nonTg mice. This could explain that the activity of gamma-secretase appears to
be profoundly suppressed in B103-wt APP cells as compared to that in nonTg mice. There
were no differences in full length APP for Tg mice or B103-wtAPP cells with and without
Rg1 treatment (Fig. 2B and 3B-C), suggesting that Rg1 does not interfere with APP
generation/production. These in vitro results support the observations made for in vivo Rg1-
treated mAPP mice both of which indicate that Rg1 treatment decreased γ secretases, which
are responsible for Aβ production.
3.3. Effect of Rg1 on neuropathologic development in Tg mAPP mice
In view of decreased Aβ accumulation in Rg1-treated mAPP brain, we next determined
whether Rg1 treatment could reverse neuropathological changes in mAPP brain. Since
diminished density of cholinergic fibers and synapses is associated with AD-like pathology
[30, 31] and because density of acetylcholinesterase (AChE)-positive neuritis was
significantly decreased in the AD-affected brain regions of mAPP mice [18, 27], we
examined AChE activity. AChE activity was determined histochemically and reported as the
area occupied by positively staining neurites in the entorhinal cortex (the area in which
cholinergic neuritis is predominant) in brain. As previously reported [18, 27], at the 12-13
months of age, mAPP mice exhibited decreased levels of AChE-positive neurites in the
entorhinal cortex compared to nonTg mice (Fig. 4; P<0.01). Such decreases in AChE-
positive fibers in mAPP brain were significantly reversed by the administration of Rg1. A
representative example of AChE histochemically stained sections of entorhinal cortex from
each group of mice is shown in the lower panel of Fig. 4. There were no differences between
Rg1-treated and vehicle-treated nonTg mice, indicating no effect of Rg1 on neuronal
structure and function. These data indicate a protective effect of Rg1 on Aβ-induced
neuropathologic alterations in mAPP mice.
3.4. Administration of Rg1 improves learning/memory in Tg mAPP mice
Based on our observations that Rg1 treatment reduced AD-type amyloidosis and
neuropathological changes, we then explored the possibility that Rg1 could improve
cognitive ability even in aged mAPP mice, whose behaviors were severely impaired by the
age of 9-13 months. Using the radial arm water maze, known to detect hippocampal-
dependent learning and memory deficits, we tested whether Rg1 treatment improves
learning and memory. At 9-13 months of age, vehicle-treated mAPP mice displayed
impaired spatial learning memory for platform location between trials (average of about 4-6
errors by trial 4 and retention test). In contrast, Rg 1-treated mAPP mice demonstrated good
spatial memory, finding the hidden platform more rapidly with increasing trials as compared
to vehicle (Fig 5; P<0.01 at age 9-10m, P<0.05 at age12-13 m). Remarkably, Rg1 treatment
for three months (from age of 6 months) completely reversed or largely improved spatial
learning/memory as shown by ∼2-3 errors on the maze compared to vehicle-treated mAPP
mice (∼ 4-6 errors by trials 4 or 5) (Fig. 5A-B). Further, Rg1 treatment markedly improved
spatial learning/memory even in aged mAPP mice with severely impaired behavior and
neuropathological impairment (Fig. 5B). Rg1 did not affect normal behavior as
demonstrated by a good performance in Rg 1 treated nonTg mice. Four groups of Tg mice
showed no difference in their speed of swimming or in the time required to reach the
platform in the visible platform test (data not shown). Taken together, these results indicate
that learning and memory improvement is a consequence of Rg1 treatment in mAPP mice.
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3.5. Rg1 activation of PKA and phosphorylation of CREB
We next explored the possible mechanisms underlying improved neuronal and cognitive
function and apparent protection in Rg1-treated mAPP mice, compared to findings in
vehicle-treated mAPP mice. cAMP-dependent protein kinase (PKA) is critical for
hippocampal-dependent long-term memory and for long-lasting potentiation (LTP) [29,
32-38]. Activation of the PKA intracellular signaling pathway has been implicated in
synaptic facilitation and enhanced memory of age-related [33, 36, 37, 39, 40] and Aß-
induced deficits [29, 32-34, 38]. Aβ is known to perturb signal transduction pathways,
including that of PKA/CREB, leading to changes in synaptic plasticity and memory [29, 33,
34]. We therefore measured PKA activity and its downstream target, phosphorylated CREB
(pCREB) in brain extracts. As shown in Fig. 6A, 12-13 month-old mAPP mice displayed
significantly decreased PKA activity as compared to nonTg littermates (P < 0.01 vs. nonTg
mice). However, Rg1 treatment for 3 months (from age 9-10 months to 12-13 month)
completely restored PKA activity. Because CREB phosphorylation depends on PKA
activity, we next measured pCREB levels in cortex extracts by ELISA. mAPP mice showed
significantly decreased CREB phosphorylation at Ser 133 compared to nonTg littermates,
whereas levels of CREB phosphorylation at serine 133 were significantly greater in Rg1-
treated Tg mAPP mice than vehicle-treated Tg mAPP mice (Fig. 6B; *P < 0.01 vs. nonTg +
vehicle, # P<0.05 vs. mAPP+vehicle). Total CREB levels were similar in Rg1-treated and
vehicle-treated mAPP mice.
To determine the direct effect of Rg1 on PKA activation and CREB phosphorylation, we
measured PKA activity and CREB phosphorylation in cultured cortical neurons exposed to
various concentrations of Rg1 (2.5, 5, and 10 μM) in the presence of Aβ. As previously
reported, treatment of cultured neurons with oligomer Aβ depressed PKA activity and
inactivated CREB phosphorylation in response to glutamate stimulation. PKA activity was
significantly decreased in neurons treated with Aβ compared to those from vehicle-treated
neurons. Notably, Rg1 abolished Aβ-induced suppression of PKA activity in a dose-
dependent manner. Similarly, in the presence of Aβ, pCREB decreased in response to
glutamate stimulation; the addition of Rg1 suppressed Aβ-induced inhibitory effects on
pCREB in a dose-dependent manner (Fig 6 C-D; * P<0.05, # P<0.01). These results strongly
suggest that inhibition of the PKA/CREB pathway underlies the effects of Aβ on synaptic
function; further Rg1 enhances PKA activity and CREB phosphorylation, and may be
responsible for protection against Aβ-induced neuronal dysfunction and cognitive decline in
mAPP mice.
4. Discussion
In the present study, we established that Rg1 treatment protects against Aβ-mediated
abnormalities in a well-characterized AD mouse model over expressing Aβ. Rg1 treatment
reversed deleterious effects in mAPP mice, and even in aged mAPP mice that had severe
neuropathological changes and impaired learning/memory.
First, we demonstrated a role of Rg-1 on regulation of γ-secretase, a potential mechanism of
Rg1-mediated reduction in Aβ accumulation in brain both in vitro Aβ-rich neuronal culture
and in vivo mAPP mice over expressing Aβ. Second, we showed a protective effect of Rg1
on Aβ-induced neuropathological changes in mAPP mice as shown by increased AChE-
positive fibers in mAPP brain upon Rg1 treatment. Third, using different transgenic AD
mouse model, an aggressive model of beta-amyloid pathology, we were able to observe the
protective effects of Rg1 as previously described in the non-AD mouse model (SAMP8
mice) [12, 13, 41]. These reproducible results in particular from a different transgenic AD
mouse model provide the additional evidence of the protective effects of Rg1 on Aβ-induced
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amyloid pathology and impaired cognitive function, which will significantly strengthen and
support the significance of Rg1 on the clinical translation application in the future.
We investigated the possible mechanisms underlying the Rg1 protection noted above. Rg1
treatment significantly inhibited γ-secretases in studies of in vitro cultured neuronal cells
and in vivo mAPP mice overexpressing Aβ. It was previously reported that oral Rg1
treatment decreased Aβ levels in the brain of Tg 2576 mice [12], but the underlying
mechanism of lower cerebral amyloid accumulation was unclear. Our results suggest the
involvement of Rg1 in modulation of APP cleavage. APP is cleaved by three secretases to
generate various distinct products. β -secretase cleaves APP at the N-terminus to form CTF-
β, which is subsequently cleaved by γ-secretase to form Aβ 40 and 42 residues [42].
Therapeutic inhibition of β- and γ-secretase decreased all forms of Aβ, including the
pathogenic Aβ42. Given that inhibition of γ-secretase decreases Aβ production,
development of compounds that inhibit and/or modulate γ-secretase activity will represent a
rational therapeutic approach for the treatment of AD. Several groups have shown that γ-
secretase inhibitor treatment results in therapeutic reduction of neurotoxic Aβ peptides [43,
44]. Rg1-mediated reduction of γ secretase activity would therefore provide additive
protection against Aβ amyloidosis. Rg1 might also be a promising therapeutic candidate for
AD due to its strong protection and low incidence of adverse effects.
The cAMP-respond element-binding protein (CREB) is important for learning and memory
and may be a core component of the molecular switch that converts memory from short-
term to long-term [45]. The major regulator of CREB activity is cAMP-dependent protein
kinase (PKA). Increases in intracellular cAMP activated PKA act to disassociate the
regulatory subunits from the catalytic subunits. Activated PKA moves into the cell nucleus,
where it phosphorylates CREB. Interestingly, recent studies have shown that PKA/CREB-
dependent signaling, which is required for long-term potentiation, is inhibited by sublethal
concentrations of Aβ in cultured hippocampal neurons in mouse models of AD or in human
AD brain [29, 33, 46-48]. Rg1 treatment increases cAMP levels in adipocytes and prevents
memory loss in aged SAMP8 mice through increased hippocampal antioxidation and up-
regulation of plasticity-related proteins including phosphor-CREB [41]. Taken together,
these studies suggest that Rg1 activates the PKA/CREB signal transduction pathway thereby
contributing to the improved or the retained cognitive function. To date, there is no report on
the effects of Rg1 on activation of the PKA/CREB pathway in an accelerating AD mouse
model.
The data presented herein clearly shows that spatial learning/memory impairment is
significantly improved in Tg mAPP mice treated with Rg1. Further, our results demonstrate
that Rg1 enhances the PKA/CREB signaling pathway in an Aβ-rich environment in mAPP
mice as well as in cultured cells. PKA activity and CREB phosphorylation play a key role in
synaptic function and memory. CREB is a key molecule in initiation of transcriptional
activation of other genes encoding proteins. It has been proposed that the effect of Aβ on
long term potentiation (a form of synaptic function) and memory is mediated by the
inhibition of phosphorylation of CREB, a transcription factor that is activated by cAMP-
dependent protein kinase (PKA) activity[29, 33]. Acute alterations in dendritic spines
induced by Aβ as well as chronic loss of spine density seen in mAPP transgenic mice are
both reversible by treatments that restore the cAMP/PKA/CREB signaling pathway [49].
Puzzo et al. demonstrated that CREB activation ameliorates synaptic function and memory
in a mouse model of amyloid deposition [50]. Therefore, Rg1-mediated activation of PKA/
CREB signal transduction mechanisms may be responsible for alleviating deficits of
learning and memory in mAPP mice. Aβ can also disrupt multiple signal transduction
pathways including Ca2+-regulated signaling pathways and oxidative stress-mediated kinase
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system. The potential effects of Rg1 on these signaling pathways require for the further
investigation.
In summary, our results clearly demonstrate the protective effect of Rg1 treatment on
cerebral Aβ accumulation, neuropathological change, and impaired learning/memory in a
transgenic mouse model for AD. Notably, Rg1 treatment is able to reverse largely Aβ-
induced deteriorated effects observed in an aged transgenic mouse model for Alzheimer
disease, which exhibits the extensive amyloid pathology and cognitive decline. The
mechanism through which Rg1 regulates APP process via decreased γ-secretase activity and
enhances PKA/CREB signaling may explain its neuroprotective role. Given that lowering
Abeta on its own so far (based on immunization or beta/gamma secretase inhibitors to
suppress Abeta production) does not appear to be sufficient for attenuating neuronal
dysfunction and improving cognitive function in AD patient, multiple targets such as PKA/
CREB or combination with agonists of neuronal and cognitive function in addition to
lowering Abeta would be therapeutic strategy for AD. Together with the previous studies,
our data indicate that Rg1 is a potential therapeutic agent for preventing and halting AD
progression.
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>Rg1 treatment inhibits activity of γ-secretases in transgenic mAPP mice> Rg1
significantly reduced cerebral Aβ accumulation >Administration of Rg1 improves
learning/memory and reverses neuropathological changes.
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Effect of Rg1 on Aβ accumulation. Panels A and B. ELISA used for the measurement of Aβ
40 (left) and Aβ 42 (right) in the hippocampus of 9 (A) and 12-13 (B) month old Tg mAPP
mice injected intraperitoneally with Rg1 (10mg/kg) daily continuously for 3 month or with
vehicle. Aβ 40 and Aβ 42 levels were significantly decreased in Rg1 injection group as
compared to vehicle. Panel C. Immunostaining for Aβ plaque using Aβ antibody (3D6) in 9
month old Tg mAPP mice injected with Rg1 or vehicle. Representative sections showed Aβ
deposits from Tg mAPP mice injected with Rg1(left) or with vehicle (right). Panel D.
Quantification of area (percentage) occupied by Aβ plaques in the indicated Tg mice. N =
5-6 mice per group. Scale bar 30 μm.
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Effect of Rg1 on γ-secretase activity in the brain of Tg mAPP mice and nonTg mice. Panel
A. Densitometry of APP C-terminal fragment cleavage by gamma secretase (APP-CTF-γ)
from indicated Tg mice at age of 12-13 m. Decreased γ-secretase activity in the cerebral
cortex assessed by APP-CTF- γ from membrane-associated APP in Tg mAPP mice injected
with Rg1 as compared to Tg mAPP mice injected with vehicle. Panel B. Representative
Western blots of brain extracts for full length APP, APP-CTF-γ and β-actin in the indicated
mice. Rg1 did not affect total APP expression, whereas the cleavage products of APP-CTF-γ
generated from membrane-bound APP were diminished in Rg1-treated mAPP mice. N = 3-5
mice per group.
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Fig. 3. Effect of Rg1 on γ-secretase activity in neuronal cells expressing wt APP
Panel A. Aβ ELISA used for measurement of Aβ1-40 and Aβ1-42 levels in the supernatant
of cultured neuronal cells (B103) stably expressed wild-type APP (wtAPP) in the presence
of Rg1 (5 and 10μM) or vehicle for 48 hours. Panel B. Representative Western blots of
cultured B103-wtAPP cells for APP and APP-CTF-γ, showing decreased APP-CTF-γ
generated from membrane associated APP because of reduced γ-secretase activity in
cultured B103-wtAPP cells treated with 5μM or 10μM Rg1 for 48 hours. Panels C-D.
Densitometry of APP (C) and APP-CTF-γ (D) immunoreactive bands in cells with and
without treatment of Rg1. (*P<0.01, #P<0.05 compared to those from vehicle-treated B103-
wtAPP cells).
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Effect of Rg1 on neuropathological findings in Tg mAPP mice. AChE activity was
determined histochemically in the entorhinal cortex of the indicated mice groups at 12-13
months of age. Quantification of density of AChE-positive neurites in the entorhinal cortex
of hippocampus in the indicated Tg mice (* P < 0.01 vs. other groups of mice, n = 4-6 mice/
group). Representative images for AChE staining in the entorhinal cortex of the indicated
mice are shown in the lower panel. Scale bar=5 μm.
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Effect of Rg1 on spatial learning/memory in Tg mAPP mice. Spatial/learning memory was
tested with the radial arm water maze at 9-10 months (left) and 12-13 months (right) of age
in the indicated groups of mice (n=5-8 male mice /group). Trials 1-4 denote acquisition trials
and trial 5 denotes retention trial. Tg mAPP mice injected with Rg1 showed improved
spatial learning memory as compared to Tg mAPP mice injected with vehicle. *P < 0.01, #
P < 0.05 vs. Tg mAPP+ vehicle.
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Rg1 activation of PKA and p-CREB pathway. Panel A. PKA activity was determined in
brain extracts of the indicated Tg mice treated with Rg1 or vehicle for three months (started
at 9 months old), respectively. Panel B. ELISA was performed to measure levels of
phosphor- and total-CREB in the cortex of the indicated Tg mice. The bar graphs of Figure
6B represented fold-increased phosphor-CREB normalized to total of CREB. There was no
significant change in the total of CREB. * p<0.05 vs. vehicle-treated nonTg mice and
#P<0.05 vs. vehicle-treated Tg mAPP mice. Panel C. Ginsenoside Rg1 attenuated the
decrease in PKA activity induced by oligomeric Aβ1-42. The cultured cortical neurons were
preincubated with ginsenoside Rg1 (0, 2.5, 5, 10 μM) for 1 hour, and then oligomeric
Aβ1-42 (5 μM) or vehicle was added to the cells. Two hours later, PKA activity in cell
lysates was measured and data were expressed as fold-increased compared to vehicle-treated
cells. Results are shown as the mean ± SEM. *P < 0.05, #P < 0.01 vs. neurons with 5.0 μM
Aβ1-42 treatment. Panel D. Modulation of glutamate-stimulated CREB phosphorylation by
oligomeric Aβ1-42. Phosphorylation is stimulated strongly by treatment with 50 μM
glutamate (Glut) for 15 min. Pretreatment with 5 μM Aβ for 2 h results in a decrease in
pCREB /T-CREB. This effect is opposed by the preincubation of 2.5/5/10 μM ginsenoside
Rg1 (Rg1-Aβ-Glut). Data are shown as the mean ± SEM. #P < 0.01 vs. neurons with 5.0μM
Aβ1-42 treatment. Studies were repeated at least three times.
Fang et al. Page 19
Biochim Biophys Acta. Author manuscript; available in PMC 2013 February 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
